| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma R Stupp, WP Mason, MJ Van Den Bent, M Weller, B Fisher, ... New England journal of medicine 352 (10), 987-996, 2005 | 23094 | 2005 |
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the … R Stupp, ME Hegi, WP Mason, MJ Van Den Bent, MJB Taphoorn, ... The lancet oncology 10 (5), 459-466, 2009 | 8122 | 2009 |
| Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma OL Chinot, W Wick, W Mason, R Henriksson, F Saran, R Nishikawa, ... New England Journal of Medicine 370 (8), 709-722, 2014 | 2664 | 2014 |
| Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 MJ Van Den Bent, AA Brandes, MJB Taphoorn, JM Kros, ... Journal of clinical oncology 31 (3), 344-350, 2013 | 1294 | 2013 |
| Short-course radiation plus temozolomide in elderly patients with glioblastoma JR Perry, N Laperriere, CJ O’Callaghan, AA Brandes, J Menten, C Phillips, ... New England Journal of Medicine 376 (11), 1027-1037, 2017 | 1026 | 2017 |
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1026 | 2014 |
| Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial DA Reardon, AA Brandes, A Omuro, P Mulholland, M Lim, A Wick, ... JAMA oncology 6 (7), 1003-1010, 2020 | 1011 | 2020 |
| MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed … AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ... Journal of Clinical Oncology 26 (13), 2192-2197, 2008 | 982 | 2008 |
| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The lancet oncology 18 (10), 1373-1385, 2017 | 966 | 2017 |
| Lomustine and bevacizumab in progressive glioblastoma W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ... New England Journal of Medicine 377 (20), 1954-1963, 2017 | 906 | 2017 |
| Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and … MJ van den Bent, AF Carpentier, AA Brandes, M Sanson, MJB Taphoorn, ... Journal of Clinical Oncology 24 (18), 2715-2722, 2006 | 856 | 2006 |
| MGMT promoter methylation in malignant gliomas: ready for personalized medicine? M Weller, R Stupp, G Reifenberger, AA Brandes, MJ Van Den Bent, ... Nature Reviews Neurology 6 (1), 39-51, 2010 | 855 | 2010 |
| High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial AJM Ferreri, M Reni, M Foppoli, M Martelli, GA Pangalis, M Frezzato, ... The Lancet 374 (9700), 1512-1520, 2009 | 720 | 2009 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 690 | 2015 |
| Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3 T Gorlia, MJ van den Bent, ME Hegi, RO Mirimanoff, M Weller, ... The lancet oncology 9 (1), 29-38, 2008 | 641 | 2008 |
| Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ... Journal of Clinical Oncology 27 (8), 1268-1274, 2009 | 639 | 2009 |
| Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial RO Mirimanoff, T Gorlia, W Mason, MJ Van den Bent, RD Kortmann, ... Journal of clinical oncology 24 (16), 2563-2569, 2006 | 626 | 2006 |
| Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study BG Baumert, ME Hegi, MJ van den Bent, A von Deimling, T Gorlia, ... The Lancet Oncology 17 (11), 1521-1532, 2016 | 489 | 2016 |
| IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for … MJ Van den Bent, HJ Dubbink, Y Marie, AA Brandes, MJB Taphoorn, ... Clinical Cancer Research 16 (5), 1597-1604, 2010 | 478 | 2010 |
| Epidemiology of glial and non-glial brain tumours in Europe E Crocetti, A Trama, C Stiller, A Caldarella, R Soffietti, J Jaal, DC Weber, ... European journal of cancer 48 (10), 1532-1542, 2012 | 399 | 2012 |
